Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity
- 17 September 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11475-11484
Abstract
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly used for obesity treatment, but real‐world adherence patterns, particularly among individuals without diabetes and paediatric patients, remain poorly characterised. We aimed to identify 12‐month GLP‐1 RA adherence trajectories among adults and paediatric patients with obesity without diabetes and to evaluate factors associated with adherence. Materials and Methods: We conducted a retrospective cohort study using 2021–2023 MarketScan commercial claims data. Individuals aged ≥ 10 years with obesity without diabetes who initiated GLP‐1 RAs were included. Adherence was measured as monthly proportion of days covered (PDC) over 12 months. Group‐based trajectory modelling was conducted separately in adult and paediatric cohorts. Multivariable logistic regression was used to identify factors associated with membership in the persistent‐user trajectory. Results: The study included 201 229 adults and 1139 paediatric patients. Five adherence trajectories were identified in each cohort. Among adults, trajectories included immediate discontinuers (19.6%), early discontinuers (23.5%), late discontinuers (20.7%), intermittent adherents (5.5%) and persistent users (30.7%), with mean annual PDC ranging from 0.10 to 0.87. Paediatric trajectory groups were more evenly distributed, with each group representing approximately 18%–22% of the cohort and persistent users comprising 20.3%. Geographic region was consistently associated with adherence, with higher odds of persistent use in the Northeast versus the South among adults (odds ratio [OR], 1.32) and paediatric patients (OR, 1.65). Conclusions: Most adults and paediatric patients with obesity had suboptimal adherence to GLP‐1 RA use over 12 months. Distinct adherence trajectories and consistent regional differences highlight opportunities to better understand and address barriers to long‐term obesity pharmacotherapy.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK133465)
- American Foundation for Pharmaceutical Education
This publication has 27 references indexed in Scilit:
- Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without DiabetesJAMA Network Open, 2026
- Discontinuation of Glucagon-Like Peptide-1 Receptor AgonistsJAMA, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the USJAMA Health Forum, 2021
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- IBM MarketScan Research Databases2021
- Treatment of children and adolescents who are overweight or obeseCurrent Problems in Pediatric and Adolescent Health Care, 2020
- The relative benefits of claims and electronic health record data for predicting medication adherence trajectoryAmerican Heart Journal, 2018
- Association between trajectories of statin adherence and subsequent cardiovascular eventsPharmacoepidemiology and Drug Safety, 2015
- Validating ICD coding algorithms for diabetes mellitus from administrative dataDiabetes Research and Clinical Practice, 2010